McAdam LLC’s Array Biopharma Inc ARRY Stock Holding History

McAdam LLC’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-19	Closed	–	–	715
2018 Q3	$0	Buy	19 +1	+6%	+$15	﹤0.01%	764
2018 Q2	$0	Sell	18 -7	-28%	-$111	﹤0.01%	874
2018 Q1	$0	Buy	+25	New	+$400	﹤0.01%	829

Other funds holding ARRY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

McAdam LLC's ARRY Position: Q4 2018 in Review

McAdam LLC sold out of Array Biopharma Inc (ARRY) in Q4 2018, closing a stake of 19 shares.

McAdam LLC first reported a position in ARRY in Q1 2018 and held it in 3 quarters. The position peaked at $0 in Q3 2018. 236 funds tracked by Wall St. Rank hold ARRY as of Q4 2018.

McAdam LLC reported no remaining Array Biopharma Inc position as of Q4 2018 after selling out during the quarter.
McAdam LLC sold 19 Array Biopharma Inc shares in Q4 2018.
McAdam LLC first reported a position in Array Biopharma Inc in Q1 2018 and held it in 3 quarters.
McAdam LLC's Array Biopharma Inc position peaked at $0 in Q3 2018.
236 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q4 2018.

Based on McAdam LLC's 13F filing for Q4 2018, filed 30 Jan 2019.